Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.

S100A4 and NMIIA promote tumor growth in glioblastoma by enhancing blood vessel functions.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Extracellular vesicles show promise as treatments but need more research for safety and effectiveness.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

The treatment combination is effective and generally safe for lung cancer.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Mitochondrial features can predict colorectal cancer outcomes and improve immunotherapy.

Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.

Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.

Multiphoton microscopy can effectively detect early endometrial cancer by analyzing collagen changes.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

Genetic differences affect breast cancer treatment success with tamoxifen in South African patients.